# Cardiac Safety Study in Patients With HER2 + Breast Cancer

> **NCT01904903** · PHASE2 · COMPLETED · sponsor: **Medstar Health Research Institute** · enrollment: 31 (actual)

## Conditions studied

- HER2 Positive Breast Cancer
- Left Ventricular Function Systolic Dysfunction

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Ado Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT01904903
- **Lead sponsor:** Medstar Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-06
- **Final completion:** 2020-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904903, "Cardiac Safety Study in Patients With HER2 + Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01904903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*